News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Tarek Sahmoud, MD

Articles by Tarek Sahmoud, MD

20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer

ByErika P. Hamilton, MD,Lajos Pusztai, MD, DPhil,Hatem Soliman, MD,Sara A. Hurvitz, MD,Krzysztof J. Grzegorzewski,Nassir Habboubi,Priya Marreddy,Tarek Sahmoud, MD,Nuhad Ibrahim, MD

April 28th 2023

21 TIP ELECTRA: An Open- Label, Multicenter, Phase 1b/2 Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2– Negative (HER2–) Breast Cancer

ByErika P. Hamilton, MD,Sung-Bae Kim,Neelima Vidula, MD,Simona Scartoni,Tarek Sahmoud, MD,Bartomeu Piza Vallespir,Kathy Puyana Theall,Nassir Habboubi,Nuhad Ibrahim, MD

April 27th 2023

55 TIP ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Women and Men With Metastatic Breast Cancer (mBC)

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Javier Cortes,Giuseppe Curigliano,Erika P. Hamilton, MD,Sara A. Hurvitz, MD,Sibylle Loibl,Simona Scartoni,Tarek Sahmoud, MD,Krzysztof J. Grzegorzewski,Nassir Habboubi,Joyce A. O’Shaughnessy

April 27th 2023

Cisplatin/Paclitaxel vs Cisplatin/Teniposide for Advanced Non-Small-Cell Lung Cancer

ByGiuseppe Giaccone, MD, PhD,Pieter E. Postmus, MD, PhD,Ted A. W. Splinter, MD,Maria Diaz-puente, MD,Nico Van Zandwijk, MD, PhD,Giorgio V. Scagliotti, MD, PhD,Andrea Ardizzoni, MD,Jan Van Meerbeeck, MD,Channa Debruyne, MD,Tarek Sahmoud, MD

April 1st 1997

A total of 332 patients with advanced non-small-cell lung cancer were randomized by the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative

Latest Updated Articles

Cisplatin/Paclitaxel vs Cisplatin/Teniposide for Advanced Non-Small-Cell Lung Cancer
April 1st 1997

Trending on CancerNetwork

Frontline Sunvozertinib Improves PFS vs Chemotherapy in EGFR+ NSCLC

FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma

The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes

Selinexor Combo Improves Spleen Volume Reduction in Myelofibrosis

Exploring the Role of Radiation Oncology in Kidney Cancer Awareness Month